Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.64 |
| ▸ | RELA | Q04206 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073577 | 0.92 | MAPT (0.64) | MAPTSMN1; SMN2RAB9APOLBKMT2A | |
| SCHEMBL14073844 | 0.86 | CYP3A4 (0.55) | MAPTSMN1; SMN2RAB9APOLBKMT2A | |
| SCHEMBL14073919 | 0.83 | CYP3A4 (0.56) | MAPTSMN1; SMN2RAB9APOLBKMT2A | |
| SCHEMBL14073920 | 0.83 | CYP3A4 (0.57) | MAPTSMN1; SMN2RAB9APOLBKMT2A | |
| SCHEMBL14073772 | 0.82 | NPC1 (0.61) | MAPTSMN1; SMN2RAB9AKMT2ACYP3A4 | |
| SCHEMBL14073802 | 0.81 | CYP3A4 (0.56) | MAPTSMN1; SMN2RAB9APOLBKMT2A | |
| SCHEMBL30444601 | 0.79 | KMT2A (0.62) | MAPTRAB9APOLBKMT2AMEN1 | |
| SCHEMBL22284873 | 0.79 | CYP3A4 (0.58) | MAPTRAB9APOLBKMT2AMEN1 | |
| SCHEMBL14073934 | 0.78 | ROCK2 (0.57) | MAPTSMN1; SMN2RAB9APOLBKMT2A | |
| SCHEMBL14073898 | 0.78 | CYP3A4 (0.59) | MAPTSMN1; SMN2RAB9APOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | MAPT 3986/4885SMN1; SMN2 3755/4885RAB9A 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.